|
AVI BIOPHARMA INC, (AVII) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
AVI BioPharma, Inc. engages in the development and commercialization of therapeutic products based on NEUGENE antisense and cancer immunotherapy technology. Its principal products in development target cardiovascular restenosis, infectious disease, cancer, polycystic kidney disease, and drug metabolism. The companys antiviral program uses NEUGENE antisense compounds to target single-stranded RNA viruses, including West Nile virus, SARS coronavirus, calicivirus, and hepatitis C. AVI BioPharmas second technology, AVICINE, is a therapeutic cancer vaccine. The company completed six human clinical trials for AVICINE, including multicenter phase II trials for colorectal cancer and pancreatic cancer. The company has strategic alliances with Exelixis, Inc.; DepoMed, Inc.; XTL Biopharmaceuticals, Ltd.; SuperGen, Inc.; and Abgenix, Inc. AVI BioPharma was incorporated in Oregon in 1980 and its principal executive offices are located in Portland, Oregon.
|
AVI BIOPHARMA INC Related |
|
AVI BioPharma Development and manufacture of sequence-specific nucleic acid binding molecules for pharmaceutical and diagnostic products.
|
|
Employment - AVI BioPharma AVI BioPharma develops therapeutic products for the treatment of life ... AVI BioPharma, Inc. Attn: Human Resources. 4575 SW Research Way, Ste 200 ...
|
|
AVII: Summary for AVI BioPharma, Inc. - Yahoo! Finance Get detailed information on AVI BioPharma, Inc. ... AVI BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial ...
|
|
